ILT17 ANTIBODY Russian patent published in 2016 - IPC C07K16/28 

FIELD: biochemistry.

SUBSTANCE: invention relates to biochemistry. Described is a monoclonal antibody, which is bound with human ILT7, not bound with any of human ILT1, ILT2 and ILT3, suppresses production of ILT7-expressing cells of interferon α (IFNα), or a fragment containing its antigen-binding area. ILT7-antibody bound with IPS cells and inhibiting them. Using the ILT7-antibodies according to the invention it is possible to inhibit activity of IPS cells and treat or prevent a disease associated with interferon. Expression of ILT7 remains in IPS cells even in presence of HLI.

EFFECT: thus, the ILT7-antibody action as an inhibitor of IPS activity can be expected even in a patient with an autoimmune disease with high production of HLI.

6 cl, 13 dwg, 7 tbl, 7 ex